Adjusted association of candidate HLA-DPB1-recipient variants with aGVHD and relapse in the replication cohort
| . | . | . | . | Unadjusted . | Clinical adjustment* . | HLA-DPB1 adjustment† . | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Variant . | Cohort . | Endpoint . | Model . | P . | HR . | LB . | UB . | P . | HR . | LB . | UB . | P . | HR . | LB . | UB . |
| rs9277378 | ALL | GVHD2b | Dominant | .01 | 1.20 | 1.0 | 1.4 | .01 | 1.20 | 1.0 | 1.4 | .31 | 1.09 | 0.9 | 1.3 |
| rs9277378 | URD | GVHD2b | Allelic | .008 | 1.28 | 1.1 | 1.5 | .01 | 1.27 | 1.1 | 1.5 | .23 | 1.21 | 0.9 | 1.7 |
| rs9277535 | URD | GVHD2b | Allelic | .01 | 1.27 | 1.1 | 1.5 | .03 | 1.24 | 1.0 | 1.5 | .49 | 1.11 | 0.8 | 1.5 |
| rs9277542 | URD | GVHD2b | Allelic | .006 | 1.28 | 1.1 | 1.5 | .008 | 1.29 | 1.1 | 1.5 | .22 | 1.22 | 0.9 | 1.7 |
| rs9277378 | ALL | Relapse | Recessive | .05 | 0.72 | 0.5 | 1.0 | .03 | 0.69 | 0.5 | 1.0 | .19 | 0.79 | 0.5 | 1.1 |
| rs9277542 | ALL | Relapse | Recessive | .04 | 0.70 | 0.5 | 1.0 | .02 | 0.68 | 0.5 | 1.0 | .16 | 0.78 | 0.5 | 1.1 |
| rs9277378 | URD | Relapse | Recessive | .03 | 0.49 | 0.2 | 1.0 | .01 | 0.44 | 0.2 | 0.9 | .18 | 0.59 | 0.3 | 1.3 |
| rs9277535 | URD | Relapse | Recessive | .02 | 0.41 | 0.2 | 1.0 | .01 | 0.37 | 0.2 | 0.9 | .12 | 0.47 | 0.2 | 1.4 |
| rs9277542 | URD | Relapse | Recessive | .01 | 0.45 | 0.2 | 0.9 | .005 | 0.41 | 0.2 | 0.8 | .13 | 0.55 | 0.2 | 1.2 |
| . | . | . | . | Unadjusted . | Clinical adjustment* . | HLA-DPB1 adjustment† . | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Variant . | Cohort . | Endpoint . | Model . | P . | HR . | LB . | UB . | P . | HR . | LB . | UB . | P . | HR . | LB . | UB . |
| rs9277378 | ALL | GVHD2b | Dominant | .01 | 1.20 | 1.0 | 1.4 | .01 | 1.20 | 1.0 | 1.4 | .31 | 1.09 | 0.9 | 1.3 |
| rs9277378 | URD | GVHD2b | Allelic | .008 | 1.28 | 1.1 | 1.5 | .01 | 1.27 | 1.1 | 1.5 | .23 | 1.21 | 0.9 | 1.7 |
| rs9277535 | URD | GVHD2b | Allelic | .01 | 1.27 | 1.1 | 1.5 | .03 | 1.24 | 1.0 | 1.5 | .49 | 1.11 | 0.8 | 1.5 |
| rs9277542 | URD | GVHD2b | Allelic | .006 | 1.28 | 1.1 | 1.5 | .008 | 1.29 | 1.1 | 1.5 | .22 | 1.22 | 0.9 | 1.7 |
| rs9277378 | ALL | Relapse | Recessive | .05 | 0.72 | 0.5 | 1.0 | .03 | 0.69 | 0.5 | 1.0 | .19 | 0.79 | 0.5 | 1.1 |
| rs9277542 | ALL | Relapse | Recessive | .04 | 0.70 | 0.5 | 1.0 | .02 | 0.68 | 0.5 | 1.0 | .16 | 0.78 | 0.5 | 1.1 |
| rs9277378 | URD | Relapse | Recessive | .03 | 0.49 | 0.2 | 1.0 | .01 | 0.44 | 0.2 | 0.9 | .18 | 0.59 | 0.3 | 1.3 |
| rs9277535 | URD | Relapse | Recessive | .02 | 0.41 | 0.2 | 1.0 | .01 | 0.37 | 0.2 | 0.9 | .12 | 0.47 | 0.2 | 1.4 |
| rs9277542 | URD | Relapse | Recessive | .01 | 0.45 | 0.2 | 0.9 | .005 | 0.41 | 0.2 | 0.8 | .13 | 0.55 | 0.2 | 1.2 |
See Table 3 for definitions.
Adjustment factors for GVHD 2b included donor type, donor-recipient gender combination, patient and donor age, marrow or growth factor-mobilized blood cell graft, intensity of the conditioning regimen and use of total body irradiation, and initial GVHD prophylaxis regimens. Adjustment factors for relapse also included the disease risk group.
Adjustment factors included the number of GVH, HVG, and bidirectional HLA-DPB1 mismatches; the number of mismatched high expression HLA-DPB1 alleles in the recipient; the presence of nonpermissive T-cell epitope mismatching; the number of HLA-A, B, C, DRB1, and DQB1 mismatches in the overall cohort.